Objective(s):To assess the levels of systemic inflammatory markers of age-associated comorbidities in people living with HIV (PLHIV) on long term suppressive antiretroviral therapy (ART).
Design:Prospective cross-sectional study in a well-defined Indian cohort of PLHIV.Methods: Blood samples were obtained from therapy naïve PLHIV (Pre-ART, n=43), PLHIV on ART for >5 years (ART, n=53), and HIV-negative healthy controls (HIVNC, n=41).Samples were analyzed for 92 markers of inflammation, sCD14, sCD163, telomere length and HIV-1 reservoir.
Results:Despite a median duration of eight years of successful ART, sCD14 (p<0.001) and sCD163 (p=0.04) levels continued to be significantly elevated in ART group as compared to HIVNC. Besides, eleven inflammatory markers, including 4E-BP1, ADA, CCL23, CD5, CD8A, CST5, MMP1, NT3, SLAMF1, TRAIL and TRANCE, were found to be significantly different (p<0.05) between the groups. Many of these markers are associated with age-related co-morbidities including cardiovascular disease, neurocognitive decline and some of these markers are being reported for the first time in the context of HIV-induced inflammation.Linear regression analysis showed a significant negative association between HIV-1positivity and telomere length (p<0.0001). in ART-group CXCL1 (p=0.048) and TGF-α (p=0.026) have a significant association with increased telomere length and IL-10RA was significantly associated with decreased telomere length (p=0.042).
Conclusions:The study identified several candidate biomarkers of age-related pre-mature aging in PLHIV on successful ART in a standardized public-health setting. This observation warrants further mechanistic studies to generate evidence to highlight the need for enhanced treatment monitoring and special interventions in HIV-infected individuals.